Iovance Biotherapeutics named Noah Berkowitz chief medical officer to lead global development of its TIL platform in solid tumors, as it expands its pipeline after raising 2026 revenue guidance to $410M-$420M on strong demand for Amtagvi and Proleukin.
published
Iovance Biotherapeutics named Noah Berkowitz chief medical officer to lead global development of its TIL platform in solid tumors, as it expands its pipeline after raising 2026 revenue guidance to $410M-$420M on strong demand for Amtagvi and Proleukin.
Latest documented BWB result
BWB member result
Exit /ES with a huge win - 56 Points or 224 ticks
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.